Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

被引：57

作者：

Pirozzi, Flora ^{[1
]}

Poto, Remo ^{[1
]}

Aran, Luisa ^{[1
]}

Cuomo, Alessandra ^{[1
]}

Galdiero, Maria Rosaria ^{[1
,2
,3
]}

Spadaro, Giuseppe ^{[1
,2
,3
]}

Abete, Pasquale ^{[1
]}

Bonaduce, Domenico ^{[1
]}

Marone, Gianni ^{[1
,2
,3
]}

Tocchetti, Carlo Gabriele ^{[1
,2
,4
]}

Varricchi, Gilda ^{[1
,2
,3
]}

Mercurio, Valentina ^{[1
]}

机构：

[1] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy

[2] Univ Naples Federico II, Ctr Basic & Clin Immunol Res, Naples, Italy

[3] Univ Naples Federico II, World Allergy Org Ctr Excellence, Naples, Italy

[4] Univ Naples Federico II, Interdept Ctr Clin & Translat Res CIRCET, Naples, Italy

来源：

CURRENT ONCOLOGY REPORTS | 2021年 / 23卷 / 02期

关键词：

Immune checkpoint inhibitors; Cardio-immuno-oncology; Cardiotoxicity; Risk factors; CANCER-IMMUNOTHERAPY; PERICARDIAL-EFFUSION; MAGNETIC-RESONANCE; EUROPEAN-SOCIETY; MYOCARDITIS; MANAGEMENT; NIVOLUMAB; EVENTS; POLYMORPHISMS; ASSOCIATION;

D O I：

10.1007/s11912-020-01002-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Immune checkpoint inhibitors, such as monoclonal antibodies targeting CTLA-4, PD-1, and PD-L1, have improved the outcome of many malignancies, but serious immune-related cardiovascular adverse events have been observed. Patients' risk factors for these toxicities are currently being investigated. Recent Findings Interfering with the CTLA-4 and PD-1 axes can bring to several immune-related adverse events, including cardiotoxic events such as autoimmune myocarditis, pericarditis, and vasculitis, suggesting that these molecules play an important role in preventing autoimmunity. Summary Risk factors (such as pre-existing cardiovascular conditions, previous and concomitant cardiotoxic treatments, underlying autoimmune diseases, tumor-related factors, simultaneous immune-related toxic effects, and genetic factors) should be always recognized for the correct management of these toxicities.

引用

页数：8

共 50 条

[41] Cardiothoracic complications of immune checkpoint inhibitors
Gosangi, Babina
Wang, Yifan
Rubinowitz, Ami N.
Kwan, Jennifer
Traube, Leah
Gange, Christopher
Bader, Anna S.
CLINICAL IMAGING, 2023, 102 : 98 - 108
[42] Immune checkpoint inhibitors related cardiovascular toxicity: 3-mounth follow-up
Kushnareva, E. A.
Gavriluk, N. D.
Shuginova, T. N.
Urumova, E. L.
Karelkina, E., V
Simakova, M. A.
Moiseenko, F., V
Moiseeva, O. M.
KARDIOLOGIYA, 2023, 63 (07) : 23 - 31
[43] The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond
Gilon, Dan
Iakobishvili, Zaza
Leibowitz, David
VACCINES, 2022, 10 (02)
[44] Rheumatic Complications of Immune Checkpoint Inhibitors
Ghosh, Nilasha
Bass, Anne R.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2022, 48 (02) : 411 - 428
[45] Skin Reactions to Immune Checkpoint Inhibitors
Patel, Anisha B.
Pacha, Omar
IMMUNOTHERAPY, 3RD EDITION, 2020, 1244 : 235 - 246
[46] Skin Reactions to Immune Checkpoint Inhibitors
Patel, Anisha B.
Pacha, Omar
IMMUNOTHERAPY, 2ND EDITION, 2018, 995 : 117 - 129
[47] Immune checkpoint inhibitors and renal toxicity
Bocchi, F.
Hafliger, S.
Schmid, S.
Sidler, D.
HELIYON, 2024, 10 (11)
[48] Cardiotoxicities associated with immune checkpoint inhibitors
Yang, Shu
Asnani, Aarti
CURRENT PROBLEMS IN CANCER, 2018, 42 (04) : 422 - 432
[49] Immune Checkpoint Inhibitors Related to Cardiotoxicity
Chen, Ru
Zhou, Min
Zhu, Feng
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2022, 9 (11)
[50] Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
Makarious, D.
Horwood, K.
Coward, J. I. G.
EUROPEAN JOURNAL OF CANCER, 2017, 82 : 128 - 136

← 1 2 3 4 5 →